COEP Is Developing Futuristic Immunotherapy That May Revolutionize Medical Industry in 2022
(CD38-Diagnostic)
diagnostic tool to analyze if
cancer patients might be
appropriate candidates for antiCD38 mAb therapy. CD38-Diagnostic provides the ability to pre-determine a patient's likelihood of benefiting from treatment. This tech may also be developed to serve as a diagnostic for a myriad of other treatments + diseases.
(CD38-GEAR-NK)
leukemia, and acute myeloid leukemia
stage biopharmaceutical company, in developing transformative treatment for Crohn's Disease. This treatment, STAT201, is a lower dose, lower cost version of an already FDA approved treatment. STAT201 decreases side effects and provides an affordable and more accessible tablet or capsule option for patients suffering from Crohn's disease.
At BigStocks.io We Dive Deeper Than The Competition To Bring You The RED HOT Stocks No One Else Is Watching
COEP Is An Undervalued Stock Showing Explosive Potential
How about BioNTech, the overlooked, tiny German company that was trading at $28.50 before March 2020? Pfizer couldn't wait to get their hands on BioNTech's mRNA tech, promptly rocketing the stock as much as 1528.07% to $464 by August 2021.
For the investors who got in at the right time, these previously under-watched BioTech innovators were the ticket to generational wealth!
But now there's another underwatched BioTech innovator that we believe could transform the medical field like Moderna and BioNTech did.
Our in depth analysis showed us that Coeptis Therapeutics (COEP) Is On track For A Massive 2022 and is a BUY NOW stock!
We believe the stock will rise 85% soon with the potential to soar to 1000+% gains by the end of the year. At BigStocks.io, we're betting big on COEP and recommend you do the same. According to our analysis a $1,000 investment today could be nearly doubled to $1,850 in a matter of weeks. That same $1,000 could rise to over $10K if COEP soars the way other BioTech innovators like it have in recent years.
Buy COEP today and watch your portfolio soar. You'll be glad you did.
Our Last 3 Stock Picks Gained An Average Of 382.7% And Our Last BioTech Buy Alert Grew 600+%
Does The Company Have:
⬇ Here are just a few things we consider during our analysis ⬇
Invest Now By Clicking The Button Below
Our Disclaimer: This website is a paid advertisement
This website/newsletter is edited, operated and owned by Delta Media Group LLC, a media company providing extensive research and important information profiling publicly traded companies trading on OTC and Nasdaq as a paid service. Wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “Delta Media” refers to Delta Media Group LLC This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small publicly traded companies. By reading our newsletter and our website content you agree to the terms of our disclaimer, which are subject to change at any time. It is important for traders to always do your own research and consult with a licensed investment professional before investing in stocks. Please conduct your own research. This communication should never be used as a basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a beginning point to do your own research and should consult with a licensed professional regarding the companies profiled on our websites and newsletters. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations.
Companies trading at lower prices per share are generally deemed to be speculative in nature and carry a higher degree of risk. Only invest money that you can afford to lose, use extreme caution when using margin trading. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to many contributing factors. By using our service you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information and content within our newsletters and website/landing pages.
Never invest solely based on our stock picks or alerts, losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. We do not advise or suggest any reader or subscriber take any specific action. Gains referenced in our website and newsletters may be based on intraday and or end-of-day trade data. This website publication and its affiliates/owners may likely hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and the number of shares here. Delta Media Group LLC business model is to receive financial compensation to advertise public companies. Pursuant to an agreement between Delta Media, and Penzance Limited Liability Company, (a non-affiliated 3rd party), Delta Media has been hired for a period beginning on 12/11/2021 and ending on 12/11/22 to conduct investor relations advertising and marketing and publicly disseminate information about (COEP) via Website, Email, and SMS. We have been paid or expect to be paid one hundred fifty thousand dollars via bank wire transfer. We expect to receive additional compensation as investor awareness continues. Delta Media, own's zero shares of (COEP). This compensation is a major conflict of interest in our ability to be unbiased to our subscribers and investors should use caution.
The third-party, profiled company or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. This communication should be viewed as a commercial advertisement only. We have not investigated the background of third-party clients who hire us or its parties.
Often companies profiled within our alerts will experience a large increase in trading volume resulting in much higher share price during the course of investor relations advertising, which may end as soon as the investor relations advertising is ended. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future compensated investor relations programs and services.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website/landing pages/newsletters. The information in our newsletters via email and on our website is believed to be accurate but has not been verified independently, and we can not guarantee this to be correct. The information is collected from public sources, such as the profiled company’s press releases, news articles, website, but is not researched or verified whatsoever to ensure the publicly available information is correct. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor copywriter’s communications regarding the profiled company(s).
Furthermore, Delta Media frequently hires independent contractor copywriters who may make errors when preparing and researching information regarding the profiled company. You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest purely based on the information contained in our written communications. The information in our disclaimers is subject to change without notice, at any time. Please See our full disclaimer here at https://bigstocks.io/disclaimer
$1.2T Treatment Market
(CD38-Diagnostic)
Here are just a few things we consider during our analysis ⬇⬇
We believe the stock will rise 85% soon with the potential to soar to 1000+% gains by the end of the year. At BigStocks.io, we're betting big on COEP and recommend you do the same. According to our analysis a $1,000 investment today could be nearly doubled to $1,850 in a matter of weeks. That same $1,000 could rise to over $10K if COEP soars the way other BioTech innovators like it have in recent years.
Buy COEP today and watch your portfolio soar.
You'll be glad you did.
At BigStocks.io We
Dive Deeper Than The Competition To Bring You The RED HOT Stocks No One Else Is Watching
